(Q51636948)

8 April 2018

title

Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation. (English)

1 reference

8 April 2018

0 references

J M Falko

1

1 reference

8 April 2018

K Osei

series ordinal

2

1 reference

8 April 2018

language of work or name

English

0 references

publication date

1 September 1985

1 reference

8 April 2018

American Journal of Medicine

published in

1 reference

8 April 2018

volume

79

1 reference

8 April 2018

issue

3B

1 reference

8 April 2018

page(s)

92-101

1 reference

8 April 2018

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Decreased Sensitivity of the Pancreatic Beta Cells to Glucose in Prediabetic and Diabetic Subjects: A Glucose Dose-Response Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Nonketotic diabetes mellitus: insulin deficiency or insulin resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Insulin binding in diabetes. Relationships with plasma insulin levels and insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Decreased insulin binding to adipocytes and circulating monocytes from obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Erythrocyte insulin receptors in non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Insulin treatment reverses the insulin resistance of type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Lipoprotein composition in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Designs for experiments--parallel comparisons of treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Effect of sulphonylurea on insulin secretion and glucose control in insulin-treated diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Receptor depletion in diabetes mellitus: correction with therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Lack of in Vivo Insulin Resistance in Controlled Insulin-Dependent, Type I, Diabetic Patients*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Determination of free and total insulin and C-peptide in insulin-treated diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

The effect of improved diabetic control on plasma lipid and lipoprotein levels: a comparison of conventional therapy and continuous subcutaneous insulin infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Diabetes Mellitus: Incidence, Prevalence, Survivorship, and Causes of Death in Rochester, Minnesota, 1945–1970

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Effects of therapy on plasma-high-density-lipoprotein-cholesterol concentration in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Insulin Therapy in Relation to Circulating C-peptide Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

C-Peptide Levels as a Criterion in Treatment of Maturity-Onset Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

C-peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Significance of spontaneous ketonuria and serum C-peptide levels in obese type II diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Reduction of C-peptide secretion in noninsulin-dependent diabetic patients with long duration of insulin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Inhibition of insulin secretion by exogenous insulin in normal man as demonstrated by C-peptide assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980014-0

10.1016/S0002-9343(85)80014-0

7 January 2021

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018